Crossref Cited-by Linking logo

Collect. Czech. Chem. Commun. 1967, 32, 1250-1257
https://doi.org/10.1135/cccc19671250

Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin

M. Zaoral, J Kolc and F. Šorm

Crossref Cited-by Linking

  • Wiśniewski Kazimierz, Qi Steve, Kraus John, Ly Brian, Srinivasan Karthik, Tariga Hiroe, Croston Glenn, La Erin, Wiśniewska Halina, Ortiz Carlos, Laporte Régent, Rivière Pierre J.-M., Neyer Gebhard, Hargrove Diane M., Schteingart Claudio D.: Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists. J. Med. Chem. 2019, 62, 4991. <https://doi.org/10.1021/acs.jmedchem.9b00132>
  • Weinberg Ruth S, Grecco Marcelo O, Ferro Gimena S, Seigelshifer Debora J, Perroni Nancy V, Terrier Francisco J, Sánchez-Luceros Analía, Maronna Esteban, Sánchez-Marull Ricardo, Frahm Isabel, Guthmann Marcelo D, Di Leo Daniela, Spitzer Eduardo, Ciccia Graciela N, Garona Juan, Pifano Marina, Torbidoni Ana V, Gomez Daniel E, Ripoll Giselle V, Gomez Roberto E, Demarco Ignacio A, Alonso Daniel F: A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. SpringerPlus 2015, 4. <https://doi.org/10.1186/s40064-015-1217-y>
  • Peyronnet B., Pradère B., Bruyère F.: Prise en charge de la nycturie : une entité nosologique au sein des troubles mictionnels de l’homme. Progrès en Urologie 2014, 24, 80. <https://doi.org/10.1016/j.purol.2013.08.310>
  • Ripoll Giselle V., Garona Juan, Pifano Marina, Farina Hernan G., Gomez Daniel E., Alonso Daniel F.: Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. Breast Cancer Res Treat 2013, 142, 9. <https://doi.org/10.1007/s10549-013-2724-6>
  • Manning M., Misicka A., Olma A., Bankowski K., Stoev S., Chini B., Durroux T., Mouillac B., Corbani M., Guillon G.: Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics. Journal of Neuroendocrinology 2012, 24, 609. <https://doi.org/10.1111/j.1365-2826.2012.02303.x>
  • Chee Sze Yin, Flegel Martin, Pumera Martin: Regulatory peptides desmopressin and glutathione voltammetric determination on nickel oxide modified electrodes. Electrochemistry Communications 2011, 13, 963. <https://doi.org/10.1016/j.elecom.2011.06.012>
  • Wiśniewski Kazimierz, Galyean Robert, Tariga Hiroe, Alagarsamy Sudarkodi, Croston Glenn, Heitzmann Joshua, Kohan Arash, Wiśniewska Halina, Laporte Régent, Rivière Pierre J-M., Schteingart Claudio D.: New, Potent, Selective, and Short-Acting Peptidic V1aReceptor Agonists. J. Med. Chem. 2011, 54, 4388. <https://doi.org/10.1021/jm200278m>
  • Andersson K.-E., Arner B.: EFFECTS OF DDAVP, A SYNTHETIC ANALOGUE OF VASOPRESSIN, IN PATIENTS WITH CRANIAL DIABETES INSIPIDUS. Acta Medica Scandinavica 2009, 192, 21. <https://doi.org/10.1111/j.0954-6820.1972.tb04772.x>
  • Lindeberg E. Gunnar G.: SOLID PHASE SYNTHESIS AND SOME PHARMACOLOGICAL PROPERTIES OF 8-D-HOMOLYSINE-VASOPRESSIN AND 1-DEAMINO-8-D-HOMOLYSINE-VASOPRESSIN. International Journal of Peptide and Protein Research 2009, 7, 395. <https://doi.org/10.1111/j.1399-3011.1975.tb02458.x>
  • Lindeberg E. Gunnar G., Melin Per, Larsson Lars-Eric: SOLID PHASE SYNTHESIS AND SOME PHARMACOLOGICAL PROPERTIES OF 8-D-HOMOARGININE-VASOPRESSIN AND 1-DEAMINO-8-D-HOMOARGININE-VASOPRESSIN. International Journal of Peptide and Protein Research 2009, 8, 193. <https://doi.org/10.1111/j.1399-3011.1976.tb02495.x>
  • Lindeberg Gunnar, Karlsson Sune M., Melin Per: SOLID PHASE SYNTHESIS AND SOME HORMONAL ACTIVITIES OF 1-DEAMINO-4-L-VALINE-8-D-HOMOLYSINE-AND 1-DEAMINO-4-L-VALINE-8-D-HOMOARGININE-VASOPRESSIN. International Journal of Peptide and Protein Research 2009, 10, 240. <https://doi.org/10.1111/j.1399-3011.1977.tb01740.x>
  • Buku Angeliki, Gazis Diana, Schwartz Irving L.: Antidiuretic and pressor activities of vasopressin analogs with L-alaninamide and D-alaninamide substitutions at position 9. International Journal of Peptide and Protein Research 2009, 23, 551. <https://doi.org/10.1111/j.1399-3011.1984.tb02757.x>
  • ZAORAL MILAN: Vasopressin analogs with high and specific antidiuretic activity. International Journal of Peptide and Protein Research 2009, 25, 561. <https://doi.org/10.1111/j.1399-3011.1985.tb02211.x>
  • WANG JIANJUN, HODGES ROBERT S., SYKES BRIAN D.: Effect of trifluoroethanol on the solution structure and flexibility of desmopressin: a two-dimensional NMR study. International Journal of Peptide and Protein Research 2009, 45, 471. <https://doi.org/10.1111/j.1399-3011.1995.tb01063.x>
  • van Kerrebroeck Philip, Nørgaard Jens Peter: Desmopressin for the treatment of primary nocturnal enuresis. Pediatric Health 2009, 3, 311. <https://doi.org/10.2217/phe.09.20>
  • Drauz Karlheinz, Kleemann Axel, Martens Jürgen: Induktion von Asymmetrie durch Aminosäuren. Angewandte Chemie 2006, 94, 590. <https://doi.org/10.1002/ange.19820940804>
  • Guillon Gilles, Pena Ana, Murat Brigitte, Derick Sylvain, Trueba Miguel, Ventura Maria A., Szeto Hazel H., Wo Nga, Stoev Stoytcho, Cheng Ling Ling, Manning Maurice: Position 4 analogues of [deamino-Cys1] arginine vasopressin exhibit striking species differences for human and rat V2/V1b receptor selectivity. J. Peptide Sci. 2006, 12, 190. <https://doi.org/10.1002/psc.710>
  • Tahara Atsuo, Tsukada Junko, Tomura Yuichi, Kusayama Toshiyuki, Momose Kazuhiro, Taniguchi Nobuaki, Suzuki Takeshi, Yatsu Takeyuki, Shibasaki Masayuki: Binding and Signal Transduction Characteristics of the Nonpeptide Vasopressin V1A Receptor-Selective Antagonist YM218 in Cultured Rat Mesangial Cells. Pharmacology 2006, 78, 81. <https://doi.org/10.1159/000095698>
  • Toumba Meropi, Stanhope Richard: Morbidity and Mortality Associated with Vasopressin Analogue Treatment. Journal of Pediatric Endocrinology and Metabolism 2006, 19. <https://doi.org/10.1515/JPEM.2006.19.3.197>
  • Andrés Miriam, Peña Ana, Derick Sylvain, Raufaste Danièle, Trojnar Jerzy, Wisniewski Kazimierz, Trueba Miguel, Serradeil-Le Gal Claudine, Guillon Gilles: Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms. European Journal of Pharmacology 2004, 501, 59. <https://doi.org/10.1016/j.ejphar.2004.08.026>
  • Getie Melkamu, Neubert Reinhard H.H: LC–MS determination of desmopressin acetate in human skin samples. Journal of Pharmaceutical and Biomedical Analysis 2004, 35, 921. <https://doi.org/10.1016/j.jpba.2004.02.009>
  • Andrés Miriam, Trueba Miguel, Guillon Gilles: Pharmacological characterization of F-180: a selective human V1avasopressin receptor agonist of high affinity. British Journal of Pharmacology 2002, 135, 1828. <https://doi.org/10.1038/sj.bjp.0704634>
  • Zaoral M., Bl�ha I., Bude???�nsk� M., Machov� A., Slaninov� J.: Non-sequential vasopressin peptides. Stereochemistry and biological activity. J. Peptide Sci. 2000, 6, 123. <https://doi.org/10.1002/(SICI)1099-1387(200003)6:3<123::AID-PSC233>3.0.CO;2-H>
  • Tahara Atsuo, Tsukada Junko, Tomura Yuichi, Wada Koh-ichi, Kusayama Toshiyuki, Ishii Noe, Yatsu Takeyuki, Uchida Wataru, Tanaka Akihiro: Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells. British Journal of Pharmacology 2000, 129, 131. <https://doi.org/10.1038/sj.bjp.0702996>
  • Jones Peter: The early history of haemophilia treatment: a personal perspective. Br J Haematol 2000, 111, 719. <https://doi.org/10.1046/j.1365-2141.2000.02243.x>
  • Jones Peter: The early history of haemophilia treatment: a personal perspective. British Journal of Haematology 2000, 111, 719. <https://doi.org/10.1111/j.1365-2141.2000.02243.x>
  • Chan W. Y., Wo Nga Ching, Stoev Stoytcho, Cheng Ling Ling, Manning Maurice: Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays. Experimental Physiology 2000, 85, 7s. <https://doi.org/10.1111/j.1469-445X.2000.tb00003.x>
  • Stoev S., Cheng L.L., Olma A., Klis W.A., Manning M., Sawyer W.H., Wo N.C., Chan W.Y.: An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids. J. Peptide Sci. 1999, 5, 141. <https://doi.org/10.1002/(SICI)1099-1387(199903)5:3<141::AID-PSC180>3.0.CO;2-6>
  • Manning Maurice, Stoev Stoytcho, Cheng Ling Ling, Wo Nga Ching, Chan W.Y.: Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists. J. Peptide Sci. 1999, 5, 472. <https://doi.org/10.1002/(SICI)1099-1387(199911)5:11<472::AID-PSC217>3.0.CO;2-A>
  • Tahara Atsuo, Tsukada Junko, Ishii Noe, Tomura Yuichi, Wada Koh-ichi, Kusayama Toshiyuki, Yatsu Takeyuki, Uchida Wataru, Tanaka Akihiro: Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells. European Journal of Pharmacology 1999, 378, 137. <https://doi.org/10.1016/S0014-2999(99)00403-3>
  • Scott Lucinda V., Medbak Sami, Dinan Timothy G.: ACTH and cortisol release following intravenous desmopressin: a dose-response study. Clin Endocrinol 1999, 51, 653. <https://doi.org/10.1046/j.1365-2265.1999.00850.x>
  • Okamura Tomio, Ayajiki Kazuhide, Fujioka Hideyuki, Toda Noboru: Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. Journal of Hypertension 1999, 17, 673. <https://doi.org/10.1097/00004872-199917050-00011>
  • Toda Megumi, Ayajiki Kazuhide, Okamura Tomio, Azuma Ikuo, Toda Noboru: Desmopressin-induced dog ciliary artery relaxation. European Journal of Pharmacology 1998, 344, 197. <https://doi.org/10.1016/S0014-2999(97)01600-2>
  • Saito Masayuki, Tahara Atsuo, Sugimoto Toru: 1-desamino-8-d-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochemical Pharmacology 1997, 53, 1711. <https://doi.org/10.1016/S0006-2952(97)00070-1>
  • Jiskra Jan, Pacáková Věra, Tichá Marie, Štulík Karel, Barth Tomislav: Use of capillary electrophoresis and high-performance liquid chromatography for monitoring of glycosylation of the peptides dalargin and desmopressin. Journal of Chromatography A 1997, 761, 285. <https://doi.org/10.1016/S0021-9673(96)00831-X>
  • Lethagen S.: Desmopressin - a haemostatic drug. European Journal of Anaesthesiology 1997, 14, 1. <https://doi.org/10.1097/00003643-199703001-00002>
  • Di Michele S., Sillen U., Engel J.A., Hjalmas K., Rubenson A., Soderpalm B.: Desmopressin and Vasopressin Increase Locomotor Activity in the Rat Via a Central Mechanism: Implications for Nocturnal Enuresis. The Journal of Urology 1996, 156, 1164. <https://doi.org/10.1016/S0022-5347(01)65743-4>
  • Ufer Elke, Postina Rolf, Gorbulev Valentin, Fahrenholz Falk: An extracellular residue determines the agonist specificity of V2 vasopressin receptors. FEBS Letters 1995, 362, 19. <https://doi.org/10.1016/0014-5793(95)00150-8>
  • Pávó I., Varga Cs., Szücs M., László F., SzÉcsi M., Gardi J., László F.A.: Effects of testosterone on the rat renal medullary vasopressin receptor concentration and the antidiuretic response. Life Sciences 1995, 56, 1215. <https://doi.org/10.1016/0024-3205(95)00061-A>
  • Horstman Lawrence L., Valle-Riestra Benjamin J., Jy Wenche, Wang Fang, Mao Wei, Ahn Yeon S.: Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity. Thrombosis Research 1995, 79, 163. <https://doi.org/10.1016/0049-3848(95)00102-W>
  • Thompson Susan, REY JOSEPH M.: Functional Enuresis: Is Desmopressin the Answer?. Journal of the American Academy of Child & Adolescent Psychiatry 1995, 34, 266. <https://doi.org/10.1097/00004583-199503000-00009>
  • Vilhardt Hans, Barth Tomislav, Melin Per, Aurell Carl-Johan: Antidiuretic activity and release of Factor VIII by vasopressin analogues. European Journal of Pharmacology 1993, 232, 223. <https://doi.org/10.1016/0014-2999(93)90777-F>
  • David Jean-Louis: Desmopressin and hemostasis. Regulatory Peptides 1993, 45, 311. <https://doi.org/10.1016/0167-0115(93)90227-Y>
  • Malerbi Domingos A., Mendonça Berenice B., Liberman Bernardo, Toledo Sergio P. A., Corradini Maria Cristina M., Cunha-Neto Malebranche B., Fragoso Maria Candida B. V., Wajchenberg Bernardo: The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol 1993, 38, 463. <https://doi.org/10.1111/j.1365-2265.1993.tb00341.x>
  • Manning Maurice, Sawyer Wilbur H.: Design, Synthesis and Some uses of Receptor-Specific Agonists and Antagonists of Vasopressin and Oxytocin. Journal of Receptor Research 1993, 13, 195. <https://doi.org/10.3109/10799899309073655>
  • Vilhardt Hans, Barth Tomislav: Tissue Plasminogen Activator Enhancing Activity of Vaso-Pressin Analogues in Monkeys: Structure-Activity Study. Journal of Receptor Research 1993, 13, 305. <https://doi.org/10.3109/10799899309073662>
  • Schulman Sam: DDAVP—The Multipotent Drug in Patients With Coagulopathies. Transfusion Medicine Reviews 1991, 5, 132. <https://doi.org/10.1016/S0887-7963(91)70200-9>
  • Vilhardt Hans, Barth Tomislav: Structure-Activity Relationships of Vasopressin Analogues on Release of Factor Viii in Dogs. Journal of Receptor Research 1991, 11, 233. <https://doi.org/10.3109/10799899109066402>
  • Hjälmås K., Sillén U.: Pharmacological Treatment of Bed-Wetting. Drug Invest 1990, 2, 17. <https://doi.org/10.1007/BF03258237>
  • Krege J.H., Katz V.L.: A proposed relationship between vasopressinase altered vasopressin and preeclampsia. Medical Hypotheses 1990, 31, 283. <https://doi.org/10.1016/0306-9877(90)90020-F>
  • Crankshaw Denis: [Arg8]vasopressin-induced contractions of rabbit urinary bladder smooth muscle. European Journal of Pharmacology 1989, 173, 183. <https://doi.org/10.1016/0014-2999(89)90517-7>
  • Schwartz J: Vasodilation associated with V2-type vasopressin activity: findings and implications. Molecular and Cellular Endocrinology 1989, 64, 133. <https://doi.org/10.1016/0303-7207(89)90138-X>
  • Stürmer E.: Vasopressin, oxytocin and synthetic analogues: The use of bioassays. Journal of Pharmaceutical and Biomedical Analysis 1989, 7, 199. <https://doi.org/10.1016/0731-7085(89)80084-6>
  • Crawford John D.: Introductory comments. The Journal of Pediatrics 1989, 114, 687. <https://doi.org/10.1016/S0022-3476(89)80882-0>
  • Harris Alan S.: Clinical experience with desmopressin: Efficacy and safety in central diabetes insipidus and other conditions. The Journal of Pediatrics 1989, 114, 711. <https://doi.org/10.1016/S0022-3476(89)80886-8>
  • K�hler M., Harris A.: Pharmacokinetics and haematological effects of desmopressin. Eur J Clin Pharmacol 1988, 35, 281. <https://doi.org/10.1007/BF00558266>
  • Grzonka Zbigniew, Gwizdała Elwira, Kasprzykowski Franciszek, ŁaneKiewicz Leszek: Circular dichroism studies of some arginine-vasopressin analogues. Biophysical Chemistry 1988, 31, 87. <https://doi.org/10.1016/0301-4622(88)80012-7>
  • Fox Anthony W., Friedman Paul A., Abel Peter W.: Vasopressin receptor mediated contraction and [3H]inositol metabolism in rat tail artery. European Journal of Pharmacology 1987, 135, 1. <https://doi.org/10.1016/0014-2999(87)90751-5>
  • ANTONI FERENC A.: Receptors Mediating the CRH Effects of Vasopressin and Oxytocin. Ann NY Acad Sci 1987, 512, 195. <https://doi.org/10.1111/j.1749-6632.1987.tb24961.x>
  • Gaffori O.J.W., De Wied D.: Time-related memory effects of vasopressin analogues in rats. Pharmacology Biochemistry and Behavior 1986, 25, 1125. <https://doi.org/10.1016/0091-3057(86)90098-5>
  • Schwartz Jeffrey, Ott Carol, Morales Orlando, Reid Ian A.: Role of antidiuretic activity in the inhibition of renin secretion by vasopressin in anesthetized dogs. Peptides 1986, 7, 91. <https://doi.org/10.1016/0196-9781(86)90067-7>
  • Antoni Ferenc A.: Characterization of high affinity binding sites for vasopressin in bovine adrenal medulla. Neuropeptides 1984, 4, 413. <https://doi.org/10.1016/0143-4179(84)90116-1>
  • Antoni Ferenc A., Holmes Megan C., Makara Gábor B., Kárteszi Mihály, László Ferenc A.: Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides 1984, 5, 519. <https://doi.org/10.1016/0196-9781(84)90080-9>
  • Drauz Karlheinz, Kleeman Axel, Martens J�rgen: Induction of Asymmetry by Amino Acids. Angew. Chem. Int. Ed. Engl. 1982, 21, 584. <https://doi.org/10.1002/anie.198205841>
  • Guillon Gilles, Butlen Daniel, Cantau Bernard, Barth Tomislav, Jard Serge: Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: Relation to adenylate cyclase activation. European Journal of Pharmacology 1982, 85, 291. <https://doi.org/10.1016/0014-2999(82)90216-3>
  • Burešová Olga, Škopková Jana: Vasopressin analogues and spatial working memory in the 24-arm radial maze. Peptides 1982, 3, 725. <https://doi.org/10.1016/0196-9781(82)90005-5>
  • Janáky T., Laczi F., László F. A.: BIOLOGICAL HALF-LIVES AND ORGAN DISTRIBUTION OF TRITIATED 8-LYSINE-VASOPRESSIN AND 1-DEAMINO-8-D-ARGININE-VASOPRESSIN IN BRATTLEBORO RATS. Ann NY Acad Sci 1982, 394, 116. <https://doi.org/10.1111/j.1749-6632.1982.tb37417.x>
  • Sawyer W.H., Grzonka Z., Manning M.: Neurohypophysial peptides design of tissue-specific agonists and antagonists. Molecular and Cellular Endocrinology 1981, 22, 117. <https://doi.org/10.1016/0303-7207(81)90086-1>
  • Burešová Olga, Škopková Jana: Vasopressin analogues and spatial short-term memory in rats. Peptides 1980, 1, 261. <https://doi.org/10.1016/0196-9781(80)90064-9>
  • Krejčí Ivan, Kupková Běla, Metyš Jan, Barth Tomislav, Jošt Karel: Vasopressin analogs: Sedative properties and passive avoidance behavior in rats. European Journal of Pharmacology 1979, 56, 347. <https://doi.org/10.1016/0014-2999(79)90265-6>
  • Leaf Alexander: Neurogenic diabetes insipidus. Kidney International 1979, 15, 572. <https://doi.org/10.1038/ki.1979.73>
  • Dunn M J, Greely H P, Valtin H, Kintner L B, Beeuwkes R: Renal excretion of prostaglandins E2 and F2alpha in diabetes insipidus rats. American Journal of Physiology-Endocrinology and Metabolism 1978, 235, E624. <https://doi.org/10.1152/ajpendo.1978.235.6.E624>
  • Slaninová J., Barth T., Franêk F.: Production of porcine antibodies with high specificity to [8-D-arginine] deamino-vasopressin (dDAVP). Experientia 1977, 33, 1661. <https://doi.org/10.1007/BF01934058>
  • Walter Roderich: Partial purification and characterization of post-proline cleaving enzyme:. Biochimica et Biophysica Acta (BBA) - Enzymology 1976, 422, 138. <https://doi.org/10.1016/0005-2744(76)90015-2>
  • Robinson Alan G.: DDAVP in the Treatment of Central Diabetes Insipidus. N Engl J Med 1976, 294, 507. <https://doi.org/10.1056/NEJM197603042941001>
  • Barth T., Rajerison M.R., Roy C., Jard S.: Activation of rat kidney adenylate cyclase by vasopressin analogues: Lack of correlation with antidiuretic activity. Molecular and Cellular Endocrinology 1975, 2, 81. <https://doi.org/10.1016/0303-7207(75)90050-7>
  • Cort J.H., Schück O., Stříbrná J., Škopková J., Jošt K., Mulder J.L.: Role of the disulfide bridge and the C-terminal tripeptide in the antidiuretic action of vasopressin in man and the rat. Kidney International 1975, 8, 292. <https://doi.org/10.1038/ki.1975.116>
  • Cort J. H., Albrecht I., Noväkovä J., Mulder J. L., Jošt K.: Regional and Systemic Haemodynamic Effects of Some Vasopressins: Structural Features of the Hormone which Prolong Activity. Eur J Clin Invest 1975, 5, 165. <https://doi.org/10.1111/j.1365-2362.1975.tb00443.x>
  • Cort J. H., Albrecht I., Nováková J., Mulder J. L., Jošt K.: Regional and Systemic Haemodynamic Effects of Some Vasopressins: Structural Features of the Hormone which Prolong Activity. European Journal of Clinical Investigation 1975, 5, 165. <https://doi.org/10.1111/j.1365-2362.1975.tb02283.x>
  • FRIC Ivo, FLEGEL Martin, ZAORAL Milan, KODICEK Milan: Circular-Dichroic Spectra of Vasopressin Analogues and Their Cyclic Fragments. Eur J Biochem 1975, 56, 493. <https://doi.org/10.1111/j.1432-1033.1975.tb02255.x>
  • Manning M., Balaspiri L., Judd J., Acosta M., Sawyer W.H.: Probing the molecular basis of antidiuretic specificity and duration of action with synthetic peptides. FEBS Letters 1974, 44, 229. <https://doi.org/10.1016/0014-5793(74)80731-3>
  • Gader A. M. A., da Costa J., Cash J. D.: 1-Desamino-8-D-Arginine Vasopressin and Fibrinolysis in Man. Scott Med J 1974, 19, 56. <https://doi.org/10.1177/003693307401900120>
  • Gader A.M.A., Da Costa J., Cash JohnD.: A NEW VASOPRESSIN ANALOGUE AND FIBRINOLYSIS. The Lancet 1973, 302, 1417. <https://doi.org/10.1016/S0140-6736(73)92805-5>
  • ARONSON A. S., ANDERSON K.-E., BERGSTRAND C. G., MULDER J. L.: TREATMENT OF DIABETES INSIPIDUS IN CHILDREN WITH DDAVP, A SYNTHETIC ANALOGUE OF VASOPRESSIN. Acta Paediatrica 1973, 62, 133. <https://doi.org/10.1111/j.1651-2227.1973.tb08080.x>
  • SCHILLINGER Ekkehard, LOGE Olaf, Schroder Eberhard, KLIEGER Erich, Lubke Klaus: Structure Activity Relationship of the Insulin-Like Effects of the Neurohypophysial Peptide Hormones. Eur J Biochem 1972, 27, 473. <https://doi.org/10.1111/j.1432-1033.1972.tb01863.x>
  • Vávra I., Machová A., Holecek V., Cort J.H., Zaoral M., Sorm F.: EFFECT OF A SYNTHETIC ANALOGUE OF VASOPRESSIN IN ANIMALS AND IN PATIENTS WITH DIABETES INSIPIDUS. The Lancet 1968, 291, 948. <https://doi.org/10.1016/S0140-6736(68)90904-5>